Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxcyte, Inc
The former Operation Warp Speed leader has apologized unreservedly for his actions, and loses positions with two biopharma companies.
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Merck’s V114 protected against all 15 targeted serotypes in the first two of 16 Phase III studies, but market leader Pfizer’s 20-valent Prevnar 13 successor is on track for a US FDA filing in late 2020.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- SutroVax, Inc.